We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What Analyst Projections for Key Metrics Reveal About TransMedics (TMDX) Q3 Earnings
Read MoreHide Full Article
Analysts on Wall Street project that TransMedics (TMDX - Free Report) will announce quarterly earnings of $0.27 per share in its forthcoming report, representing a decline of 59.1% year over year. Revenues are projected to reach $181.81 million, increasing 26.4% from the same quarter last year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
In light of this perspective, let's dive into the average estimates of certain TransMedics metrics that are commonly tracked and forecasted by Wall Street analysts.
The consensus among analysts is that 'Revenue- Service' will reach $74.65 million. The estimate indicates a change of +33% from the prior-year quarter.
The consensus estimate for 'Revenue- Net Product' stands at $109.20 million. The estimate indicates a year-over-year change of +24.6%.
It is projected by analysts that the 'OCS transplant revenue- United States- Total' will reach $176.03 million. The estimate indicates a year-over-year change of +26.6%.
According to the collective judgment of analysts, 'OCS transplant revenue- All other countries- Total' should come in at $4.63 million. The estimate points to a change of +27.5% from the year-ago quarter.
Over the past month, TransMedics shares have recorded returns of -16.1% versus the Zacks S&P 500 composite's -2% change. Based on its Zacks Rank #3 (Hold), TMDX will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
What Analyst Projections for Key Metrics Reveal About TransMedics (TMDX) Q3 Earnings
Analysts on Wall Street project that TransMedics (TMDX - Free Report) will announce quarterly earnings of $0.27 per share in its forthcoming report, representing a decline of 59.1% year over year. Revenues are projected to reach $181.81 million, increasing 26.4% from the same quarter last year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
In light of this perspective, let's dive into the average estimates of certain TransMedics metrics that are commonly tracked and forecasted by Wall Street analysts.
The consensus among analysts is that 'Revenue- Service' will reach $74.65 million. The estimate indicates a change of +33% from the prior-year quarter.
The consensus estimate for 'Revenue- Net Product' stands at $109.20 million. The estimate indicates a year-over-year change of +24.6%.
It is projected by analysts that the 'OCS transplant revenue- United States- Total' will reach $176.03 million. The estimate indicates a year-over-year change of +26.6%.
According to the collective judgment of analysts, 'OCS transplant revenue- All other countries- Total' should come in at $4.63 million. The estimate points to a change of +27.5% from the year-ago quarter.
View all Key Company Metrics for TransMedics here>>>Over the past month, TransMedics shares have recorded returns of -16.1% versus the Zacks S&P 500 composite's -2% change. Based on its Zacks Rank #3 (Hold), TMDX will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .